Jonathan Milner
Co-Founder @ Milner Centre for Evolution
Cambridge, United States
Jonathan Milner is a seed investor at Milner Centre for Evolution in Cambridge focused on Biotechnology and Health Care. Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
- Total investments:
- 62
- Last investment:
- Lead investor:
- 19%
Last updated:
For AI agents: llms.txt
Industries Jonathan Milner invests in
Stages Jonathan Milner invests in
Countries Jonathan Milner invests in
Round sizes
Round size
- Seed
- $537k–$25M
- Series A
- $4.1M–$50M
- Series B
- $1.6M–$56M
Investment Focus
Industry
- Biotechnology 32 (52%)
- Health Care 19 (31%)
- Medical 16 (26%)
- Life Science 10 (16%)
- Pharmaceutical 9 (15%)
Stage
- Seed 22 (35%)
- Series A 12 (19%)
- Series B 8 (13%)
- Series C 6 (10%)
- Funding Round 4 (6%)
Country
- United Kingdom 37 (60%)
- United States 2 (3%)
- Spain 1 (2%)
- Canada 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nuclera
|
Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery. | $12M / Series C / Jan 13, 2026 | |
Quibim
|
Quibim, with headquarters in Valencia, Spain, is a global leader in whole-body medical imaging analysis. Quibim products are used worldwide by leading pharmaceutical companies and research teams. Partners use Quibim Precision®, a whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy ofnovel treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers. We understand every body part. We speak human. | $50M / Series A / Jan 28, 2025 | |
52 North Health
|
52 North Health aims to improve healthcare with a medical device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy. | $6M / Dec 03, 2024 | |
Exciting Instruments
|
Exciting Instruments Limited is a joint company founded in Sheffield that combines the software prowess of Bulldozer Limited with Dr. Timothy Craggs' knowledge of single molecules. Through the use of cloud connectivity and real-time data visualisation, we are a genuine science and software partnership on a mission to assist you in streamliningthe procedure for creating discoveries in biophysics, life sciences, drug discovery, and medical diagnostics. | $5M / Seed / Nov 25, 2024 | |
Epitopea
|
Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. | $31M / Seed / Oct 24, 2024 | |
Shift Bioscience
|
Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of aging. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high-throughput, high-accuracy aging biomarker, which has been leveraged inside AI-based cell simulations toidentify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes accessible by simple prescription. | $16.3M / Seed / Oct 15, 2024 | |
|
Nuclera
|
Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery. | $75M / Series C / Oct 15, 2024 | |
Clock Bio
|
Clock Bio operates as a biotech company, that develops novel regenerative medicines. | $5.3M / Seed / Oct 09, 2024 | |
LIfT BioSciences
|
LIfT Biosciences is a biotech company that develops allogeneic cell therapies using Immunomodulatory Alpha Neutrophils (IMANs) derived from hematopoietic or induced pluripotent stem cells. The company leverages its patented N‑LIfT platform to generate neutrophils capable of directly destroying cancer cells and reprogramming the tumormicroenvironment to enhance immune recruitment. Preclinical data have shown potent activity across multiple solid tumor types, with Phase I clinical trials in metastatic cervical and head‑and‑neck cancer planned in partnership with the University of Galway. | $13.4M / Series A / Sep 24, 2024 | |
Constructive Bio
|
Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things. | $57.7M / Series A / Sep 24, 2024 | |
| See all 62 investments → | |||
Co-Investors
About Milner Centre for Evolution
Milner Centre for Evolution brings together our intellectual expertise in evolution research in a state-of-the-art research facility.
Milner Centre for Evolution Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jonathan Milner
Co-Founder
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Jonathan Milner invest in?
Jonathan Milner invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 62 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Jonathan Milner's check size?
Jonathan Milner typically joins rounds of $537k–$25M at Seed, $4.1M–$50M at Series A and $1.6M–$56M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Jonathan Milner participates in.
When did Jonathan Milner last invest?
The most recent investment recorded for Jonathan Milner closed in Jan 2026. Shizune tracks 62 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
